HK Innoen announced on June 9 that its Chinese partner, Sciwind Biosciences Co., Ltd. (Sciwind), presented the results of a head-to-head phase 2 clinical trial of the GLP-1 (glucagon-like peptide-1) class obesity treatment ecnoglutide at the '2026 American Diabetes Association (ADA)' conference, held in New Orleans, USA, from June 5 to 8 (local time).


Ecnoglutide is the world's first cAMP (cyclic adenosine monophosphate)-biased GLP-1 receptor agonist class drug, designed to enhance signaling selectivity and thereby secure both efficacy and safety. HK Innoen introduced this drug in 2024 and is currently conducting phase 3 clinical trials in Korea as a treatment for obesity and diabetes.

Linong Ji, Professor of Endocrinology at Peking University People's Hospital, presented the clinical results of ecnoglutide at the 2026 American Diabetes Association (ADA) conference. HK Innoen

Linong Ji, Professor of Endocrinology at Peking University People's Hospital, presented the clinical results of ecnoglutide at the 2026 American Diabetes Association (ADA) conference. HK Innoen

View original image

This study was a direct comparison trial between ecnoglutide and semaglutide, confirming the clinical superiority of ecnoglutide in terms of weight loss and key metabolic indicators. The trial was conducted at 17 research centers in China and involved 163 adult patients with obesity. Participants were randomly assigned in a 1:1 ratio to receive either ecnoglutide or semaglutide as a 2.4 mg maintenance dose via subcutaneous injection once a week.


The results showed that at week 20, ecnoglutide demonstrated a more pronounced weight loss effect compared to semaglutide. The average percentage reduction in body weight was 35% higher than that of semaglutide, and the proportion of patients who lost more than 10% of their body weight was about twice as high. Least squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group (P<0.0001). The proportion of participants who lost at least 10% of their body weight was 74% in the ecnoglutide group, compared to 40% in the semaglutide group (P<0.001).


Ecnoglutide also showed superior effects in reducing waist circumference compared to semaglutide. At week 20, the ecnoglutide group had an average reduction of 10.5 cm from baseline, while the semaglutide group had a reduction of 8.7 cm (P<0.05), confirming a 20% greater reduction with ecnoglutide. Other body measurements, including arm and neck circumference, also improved more significantly with ecnoglutide than with semaglutide.


In addition, ecnoglutide demonstrated better tolerability regarding gastrointestinal side effects compared to existing GLP-1 class therapies, while also achieving robust weight loss efficacy and safety. Unlike existing therapies that activate all pathways for weight loss signaling, ecnoglutide is designed with cAMP bias to enhance signaling selectivity, maximizing efficacy while minimizing signals related to side effects.


Linong Ji, Professor at Peking University People's Hospital and principal investigator of the study, stated, "These results are an important example of the clinical superiority of biased GLP-1 agonists over existing therapies and could set a new standard in the treatment paradigm for obesity and metabolic diseases."


Hai Pan, CEO of Sciwind Biosciences, emphasized, "Ecnoglutide is not just an extension of GLP-1, but an innovative, mechanism-based therapy expected to play a significant role in the global market."


Dalwon Kwak, CEO of HK Innoen, commented, "This presentation once again confirmed the potential and promise of ecnoglutide. We will do our utmost to develop this treatment so that we can offer a new therapeutic option to patients in Korea."



In 2024, HK Innoen signed a license and partnership agreement with Sciwind, a Chinese biopharmaceutical company specializing in GLP-1 peptide research and development, for the domestic development and commercialization of the GLP-1 receptor agonist ecnoglutide (project name at HK Innoen: IN-B00009).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing